Marksans Pharma Limited — Board Meeting, 12-08-2026: Outcome of Board Meeting

Marksans Pharma's board approved Q1 FY27 consolidated results. Revenue surged to ₹840.80 Cr, with PAT at ₹157.17 Cr (EPS ₹3.47). The company acquired Netherlands-based QliniQ B.V. for EUR 7.50 Million and Germany's ABCnow GmbH for EUR 1.10 Million, bolstering its European presence. Additionally, 300,000 stock options were granted.